62nd ASH Annual Meeting and Exposition: 605. Molecular Pharmacology, Drug Resistance

Oral and Poster Abstracts
Poster

Biological, antibodies, therapy sequence, ALL, apoptosis, Leukemia, Non-Biological, cell division, CLL, Diseases, drug-drug interaction, Therapies, CAR-Ts, Combinations, Mantle Cell Lymphoma, chemotherapy, Adverse Events, cellular interactions, Non-Hodgkin Lymphoma, enzyme inhibitors, B-Cell Lymphoma, Biological Processes, DLBCL, Technology and Procedures, Lymphoid Malignancies, Clinically relevant, genomics, pharmacology, TKI, NGS, microenvironment, molecular interactions, RNA sequencing, pathways, proteomics, signal transduction

966

Modulation of the Tumor Suppressor Protein PP2A Using a Small Molecule Agonist Overcomes Multi-Drug Resistance through Mitochondrial Permeability Transition Pore (MPTP) Dependent Induction of Apoptosis in Chronic Lymphocytic Leukemia

Kallesh D. Jayappa, PhD^1,2, Caroline Farrington, PhD³^*, Vicki L. Gordon, BS^1,2^*, Shekhar Saha, PhD⁴^*, Christopher Morris, BS^1,2^*, Krista M. Isaac, MD⁵^*, Timothy P. Bender, PhD^1,2^*, Michael E. Williams, MD^6,7^*, Craig A. Portell, MD^6,8, Goutham Narla, MD, PhD³^* and Michael J. Weber, PhD^1,2,6^*

¹Beirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA
²Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA
³Department of Medicine, University of Michigan, Ann Arbor, MI
⁴Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA
⁵Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA
⁶Cancer Center, University of Virginia, Charlottesville, VA
⁷Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA
⁸Division of Hematology/Oncology, University of Virginia, Charlottesville, VA

967

Overcoming Multidrug Resistance in B Cell Malignancies By Antagonism of Stromal Mediated TGF-β Signalling

Eugene Park, PhD¹^*, Jingyu Chen, PhD²^*, Andrew Moore, PhD²^*, Michael Leitges³^*, Seth E. Frietze, PhD⁴^* and Ingo Ringshausen, MD²

¹University of Cambridge, Cambridge, ENG, United Kingdom
²University of Cambridge, Cambridge, United Kingdom
³Memorial University of Newfoundland, St. John`s, Canada
⁴Vermont Cancer Center, University of Vermont, Burlington, VT

968

BET Protein Antagonist-Based Therapy of Novel Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)

Warren Fiskus, BSc, PhD¹, Christopher Peter Mill, PhD, BA²^*, Bernardo H Lara³^*, Christine Birdwell⁴^*, Michael R Green, PhD⁵, Joseph D. Khoury, MD⁶ and Kapil N. Bhalla, MD¹

¹Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
²MD Anderson Cancer Center, Houston, TX
³Leukemia, MD Anderson Cancer Center, Houston, TX
⁴The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX
⁶Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX

969

Carfilzomib-Induced Cardiotoxicity in an In Vivo Model of Aging

Panagiotis Efentakis, PhD¹^*, Garyfallia Psarrakou¹^*, Panagiota-Efstathia Nikolaou, PhD¹^*, Michael Chatzistefanou, PhD¹^*, Eleni-Dimitra Papanagnou, PhD²^*, Efstathios Kastritis, MD³^*, Ioannis P. Trougakos, PhD²^*, Meletios A Dimopoulos⁴, Ioanna Andreadou, PhD¹^* and Evangelos Terpos, MD, PhD⁴

¹Laboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece
²Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece
³Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, ATHENS, Greece
⁴Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

970

Karonudib Has Potent Anti-Tumor Effects in Preclinical Models of B-Cell Lymphoma

Morten P Oksvold, PhD, MSC^1,2^*, Ulrika Warpman Berglund, PhD³^*, Helge Gad, PhD^3,4^*, Baoyan Bai, PhD^5,6^*, Trond Stokke, PhD⁷^*, Idun D Rein, Msc⁷^*, Therese Pham³^*, Kumar Sanjiv, PhD³^*, Geir Frode Øy, PhD⁸^*, Jens Henrik Norum, PhD⁹^*, Erlend B. Smeland, PhD, MD^10,11^*, June Helen Myklebust, PhD^10,11, Thomas Helleday, PhD^3,12^* and Thea Kristin Våtsveen, PhD^13,14^*

¹KJ Jebsen Centre for B cell malignancies, University of Oslo, Oslo, Norway
²Oslo University Hospital, Institute for Cancer Research, Oslo, NOR
³Scilifelab, Karolinska Institute, Stockholm, Sweden
⁴Weston Park Cancer Centre, University of Sheffield, Sheffield, United Kingdom
⁵Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, OSLO, Norway
⁶KG. Jebsen Centre for B cell malignancies, University of Oslo, Oslo, Norway
⁷Department of Radiation Biology, Oslo University Hospital, Institute for Cancer Research, Oslo, Norway
⁸Department of Tumor Biology, Oslo University Hospital, Institute for Cancer Research, Oslo, Norway
⁹Department of Cancer Genetics, Oslo University Hospital, Institute for Cancer Research, Oslo, Norway
¹⁰Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
¹¹KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway
¹²Weston Park Cancer Centre, University of Sheffield, Sheffield, Tuvalu
¹³Department of Cancer Immunology, Oslo University Hospital, Institute for Cancer Research, Oslo, Norway
¹⁴KG Jebsen Centre for B cell malignancies, University of Oslo, Oslo, Norway

971

Cfi-400945 Induces Cytokinesis Failure By Activating Hippo Signaling Pathway in Diffuse Large B-Cell Lymphoma

Yi Zhao, MM¹^*, Juan Yang, PhD¹^*, Jiarui Liu¹^*, Shuai Ren, MM¹^*, Yiqing Cai¹^*, Shunfeng Hu, MM¹^*, Xiangxiang Zhou, MD^1,2^* and Xin Wang, MD, PhD^1,3

¹Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
²Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
³Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

972

Pharmaocogenomic Characterization of MCL-1 Inhibitor Response and Resistance in Aggressive B-Cell Lymphomas

Michelle Wang, BSE¹^*, Tao Li, MD²^*, Yuan Ren, Ph.D.³^*, Bijal Shah, MD¹, Tint Lwin, MD, PhD⁴^*, Jing Gao, PhD⁵^*, Kenneth H. Shain, MD, PhD ⁶, Wei Zhang, PhD⁷^*, Xiaohong Zhao, MD, PhD¹^* and Jianguo Tao, MD, PhD¹

¹Moffitt Cancer Center, Tampa, FL
²Moffitt Cancer Center & Research Institute, Tampa, FL
³H. Lee Moffitt Cancer Center, Tampa, FL
⁴H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
⁵Moffitt Cancer Center, Tampa
⁶Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Saint Petersburg, FL
⁷Univeristy of Central Florida, Orlando, FL

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

605.P1.21 605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Poster I